SCHEMBL10073467

SCHEMBL10073467

O=S(=O)(c1n[nH]c2ncccc12)N1CCCC1c1cccnc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.57
CYP2C19 P33261 1/20 0.57
ALDH1A1 P00352 7/20 0.54
USP2 O75604 1/20 0.54
POLB P06746 2/20 0.54
ADRB2 P07550 3/20 0.51
NUDT1 P36639 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.48
MAPT P10636 5/20 0.46
LMNA P02545 3/20 0.46
MAPK1 P28482 2/20 0.46
HTT P42858 2/20 0.46
TP53 P04637 1/20 0.46
CHRNA7 P36544 2/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNB4 P30926 2/20 0.46
CHRNA3 P32297 2/20 0.46
CHRNA4 P43681 2/20 0.46
CHRNA2 Q15822 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10072892 0.97 CYP3A4 (0.62) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL10073640 0.82 ALOX15 (0.49) ALDH1A1KMT2ALMNAHTTTDP1
SCHEMBL10072901 0.79 PIM1 (0.44) ALDH1A1USP2POLBTSHRKMT2A
SCHEMBL10072922 0.79 ALOX15 (0.54) ALDH1A1KMT2ALMNAHTTTDP1
SCHEMBL10072913 0.78 COMT (0.42)
SCHEMBL10074046 0.77 NAMPT (0.49)
SCHEMBL24016026 0.76 CYP3A4 (0.66) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL26465275 0.76 CYP3A4 (0.66) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL24015601 0.76 CYP3A4 (0.66) CYP3A4CYP2C19ALDH1A1USP2POLB
SCHEMBL17962409 0.75 POLB (0.61) CYP3A4CYP2C19ALDH1A1USP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445681-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-21 US disclosed
EP-2514751-A1 Azaindazoles useful as inhibitor of kinases Vertex Pharmaceuticals, Inc. (US) 2012-10-24 EP disclosed
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-28 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases PRKDC, MAP3K20, PRKACA CYP3A4 2515/4885CYP2C19 2166/4885ALDH1A1 3237/4885
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES PRKDC, MAP3K20, PRKACA CYP3A4 2515/4885CYP2C19 2166/4885ALDH1A1 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.